I NFANTILE HEMANGIOMAS ARE THE most common tumor of infancy and have a well-described natural history of rapid growth during early infancy followed by gradual involution. Although there are other types of vascular tumors sometimes referred to under the umbrella term hemangiomas (eg, lobular capillary hemangioma [pyogenic granuloma]), hereafter in this article the term hemangioma will refer to infantile hemangiomas specifically. The duration of the growth phase can be variable, but it has long been reported that most hemangiomas reach their maximal size within the first 6 to 10 months of life. [1] [2] [3] The growth characteristics of hemangiomas were more rigorously evaluated in a recent large prospective study, 4 which found that the early proliferative growth phase was essentially complete by 5 months of age, and overall growth was nearly always complete before 9 months of age. Although hemangiomas with growth after 9 months of age represent only a small subset, their continued growth can cause therapeutic challenges, functional sequelae, and considerable parental anxiety.
The classification of infantile hemangiomas has been based on their depth of soft-tissue involvement described as superficial, deep,orcombined.Deephemangiomashave been observed to have a longer growth phase compared with superficial hemangiomas. 2, 5 More recently, hemangiomas have also been characterized by their spatial configurations as segmental, localized, or indeterminate. Segmental hemangiomas have a geographic pattern over a cutaneous territory that frequently corresponds to a developmental segment. 6 Previous studies [7] [8] [9] have found that segmental hemangiomas are more likely to result in complications, such as ulceration, and are more likely to require treatment than localized hemangiomas. Segmental hemangiomas may also have a greater propensity to grow after 6 months of age. 4 In addition, anatomic location may be associated with a greater propensity for aggressive growth and recalcitrance to therapy. Hemangiomas involving the parotid gland have been reported to involute more slowly and be less responsive to treatment, although the latter is controversial. [9] [10] [11] [12] This retrospective case series focusing on hemangiomas with unusually prolonged growth was undertaken to further characterize this small but important subset of hemangiomas.
METHODS
Prolonged growth was defined as a proliferative growth phase past 9 months of age with-
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out treatment, or rebound growth after 1 year of age with treatment. Patients meeting inclusion criteria were identified by clinicians at the following participating institutions: the Using medical records, including photographs of all patients, a retrospective medical chart review was performed to collect data on the clinical characteristics, treatment, and outcome of patients with infantile hemangiomas identified as having prolonged growth. Hemangiomas were diagnosed based on medical history and clinical appearance, aided by imaging only when clinically indicated. Size was reported as the surface area of involvement in centimeters squared using the longest diameter and the measurement perpendicular to it. Lesions were classified as superficial, deep, or combined and as segmental, localized, or indeterminate by unblinded author agreement using previously defined criteria. 6, 8, 9 Segment numbers for facial lesions were assigned according to the patterns identified by Haggstrom et al 6 with segment 1 (S1) corresponding to the frontotemporal region; segment 2 (S2), the maxillary region; segment 3 (S3), the mandibular region; and segment 4 (S4), the frontonasal region. Response to treatment was based on the clinical assessment of the physician(s) caring for these infants.
RESULTS
We identified 23 patients with infantile hemangiomas meeting our criteria for prolonged growth. The characteristics of these patients and their hemangiomas are summarized in the Table. Eighteen (78%) of the patients were female. The hemangiomas were all located on the head and neck region, although 3 (cases 3, 19, and 23) had lesions extending onto the trunk. Absolute size measurements were not available for all lesions because 6 were noted as being too large to accurately measure. Of the 17 cases with measurements available, the mean (SD) size was 126 (103) cm 2 (range, 5-315 cm 2 ). Eighteen (78%) were segmental lesions, and the other 5 (22%) were indeterminate. Segment 3 was the most commonly represented, involved in 11 cases (48%). Six (26%) were defined as deep lesions and 17 (74%) as combined lesions.
The parotid gland was involved in 9 patients (39%). Three (13%) had clinically significant airway involvement, but only 1 (4%) (case 23) required a tracheostomy. Other complications included ulceration in 12 cases (52%) and growth failure in 5 cases (22%). Three patients (13%) (cases 15, 21, and 23) required gastrostomy tube placement. One patient (4%) (case 3) had congestive heart failure, and 1 patient (4%) (case 21) was found to have a cardiomyopathy thought to be related to high cardiac output demand of the hemangioma or possibly secondary to treatment. None of the patients had hypothyroidism.
The age at last documented growth ranged from 10 to 44 months, with a mean (SD) age of 17.3 (8.0) months. Twenty-one patients (87%) received systemic corticosteroids (CS), and 12 (52%) had additional therapies, including vincristine sulfate, interferon alfa-2a or alfa-2b, pulsed-dye laser, embolization, and debulking surgery. Two patients (9%) (cases 10 and 11) did not receive any treatments, and 1 patient (4%) received only a very brief course of treatment with discontinuation after 1 month because of problems with health insurance. The mean (SD) age at initiation of CS treatment was 3.2 (2.6) months (range, 3 weeks to 1 year). Starting dosages of CS ranged from 2.5 to 3.1 mg/kg/d, and 1 patient's dosage (case 17) was increased to 4 mg/kg/d shortly after initiation of treatment owing to poor response. The mean total duration of CS treatment was 11.2 (2.9) months, but CS treatment was intermittent rather than continuous in 10 patients. Thirteen of 19 patients (68%) had an initial decrease in size or growth cessation of their lesion, but the others had slowed or continued growth. (Data documenting initial response was lacking in 2 patients.) All patients had rebound growth during or after the CS taper, except 1 patient (case 3) who was given vincristine during the CS taper after no initial response. In several cases in which alternateday steroids were used as part of a CS taper, parents reported growth on the "off" days when steroids were not administered. Common complications of CS treatment included Cushingoid features, irritability, and difficulty sleeping. Two patients (cases 17 and 23) had elevated blood pressure. Five patients had somatic growth delay that could have been the result of CS therapy, but conceivably may have been the result of the increased metabolic demands of a very large vascular tumor or difficulties in feeding because of a mass effect.
Vincristine was the most common second-line treatment, used in 6 patients. Two patients had central catheter infections, 1 caused by Candida, and 1 resulting in bacterial sepsis. Two patients received interferon therapy, both initiated after 18 months of age, without neurologic sequelae. The mean (SD) age at which all systemic therapy was complete was 19.9 (8.1) months.
COMMENT
This case series highlights the clinical characteristics and treatments of 23 infants with infantile hemangiomas with unusually prolonged growth. To our knowledge, there have been no previous case series focusing on the "outliers" with late, ongoing growth. A recent prospective study 4 on the growth characteristics of 526 hemangiomas found that patients reached the late proliferative stage at a mean (SD) age of 6.2 (2.5) months, whereas the lesions reported herein grew until a mean (SD) age of 17.3 (8.0) months (range, up to 44 months).
All of the hemangiomas in this series were classified as segmental or indeterminate, a contrast to their incidence in a large prospective study 9 in which only 453 of 1530 (29.6%) were classified as segmental or indeterminate. Segmental hemangiomas have been found to have higher rates of complications and need for treatment, and segmental morphologic characteristic is the single greatest predictor of risk of complications and need for treatment. [7] [8] [9] Segmental hemangiomas are on average 10 times larger than lo-(REPRINTED) ARCH DERMATOL/ VOL 144 (NO. 12), DEC 2008 calized hemangiomas, 4 and our cases were no exception, with a mean (SD) area of involvement of 125 (103) cm 2 . The size and patterns of segmental hemangiomas on the face respect anatomic boundaries corresponding to embryologic neuroectodermal derivatives, suggesting an error in development as early as 6 to 8 weeks of gestation. 6 Their more aggressive clinical behavior may hypothetically be attributed to a more pervasive developmental defect not present in localized hemangiomas.
In a recent prospective study, 9 53% of hemangiomas had only a superficial component (Anita N. Haggstrom, MD, e-mail communication, November 2007), yet in our study all were either deep or both superficial and deep. Previous studies 2,4,5 have suggested that deep hemangiomas may have a longer proliferative phase. In our cases, the component subjectively assessed to have prolonged growth was typically the deep component (Table and  Figures 1-3 ). Our series also had an overrepresentation of hemangiomas involving the parotid gland (39%). Some authors [10] [11] [12] have asserted that parotid hemangiomas involute more slowly and are more resistant to systemic therapy than other hemangiomas. The findings in our 
Abbreviations: ACs, additional complications; ASI, adjacent structures involved; B, bilateral; C, combined; D, deep; EAs, extracutaneous abnormalities; GF, growth failure; Ind, indeterminate; L, left; LDG, last documented growth; NA, not available; PHACES, syndrome of posterior fossa malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities, sternal defects and/or supraumbilical raphe; R, right; S, superficial; Seg, segmental; Ulc, ulceration. a S1 through S4 refer to facial segmental patterns of infantile hemangiomas as described by Haggstrom et al. 6 b Size reported was maximal area of cutaneous involvement measured by a physician. cases support the concept of true differences in behavior in deep hemangiomas, including those with parotid involvement, rather than simply being an observational bias, and raise the question of whether the milieu in deeper sites is more permissive for growth than in more superficial sites. Parotid glands may have a higher-thannormal rate of blood flow, 11 and Blei and Rutkowski 13 noted high blood flow in hemangiomas at certain sites, particularly the parotid gland, but also the upper extremity, upper lip, and scalp, and suggested that they are "transiently arterialized," causing slower involution than at other anatomic sites. Nearly all patients were treated with systemic CS, and a substantial minority received other systemic treatments. Most responded initially to CS but had rebound growth during or after steroid taper. This occurred despite treatment with CS for prolonged periods of time; the mean duration of treatment was 11 months-substantially longer than in other reported case series in which the mean duration of treatment was 6 to 8 months. 11, 14, 15 Although the mechanisms of action of CS are only partially understood, 16, 17 Ritter et al 18 proposed that infantile hemangioma involution stems from immune recognition of the aberrant hemangioma vascular phenotype, inciting an immune response targeted at hemangioma endothelial cells. Based on this model and our findings, we hypothesize that segmental hemangiomas represent a more fundamental developmental defect than localized hemangiomas and that those involving deeper tissues, particularly the parotid gland, are more impervious to immune recognition and sustained involution. Identifying a therapy that would function by triggering immune recognition of hemangioma endothelial cells may be a possible therapeutic strategy.
This study has several limitations related to its retrospective design. There is a potential for case selectiv- ity based on recall bias. Data were accrued via medical chart review and were not documented in a systematic manner, and several patients were initially treated at other institutions. Some data required subjective clinical assessment, such as response to treatment and the characterization of lesions as deep or superficial, and as segmental or localized. Previous studies, 7,9 however, have shown good interobserver agreement for these classifications. Further large prospective studies following lesions at regular intervals are needed to more rigorously document growth and treatment of infantile hemangiomas, including those with unusually prolonged growth.
CONCLUSIONS
Most infantile hemangiomas follow a well-described natural history of proliferation within the first 5 to 6 months of life, followed by slow, gradual involution. Some hemangiomas, however, demonstrate a more prolonged growth pattern and pose distinct clinical challenges. In this study, prolonged growth was observed primarily in hemangiomas with a deep com-ponent and segmental morphologic characteristics, types of hemangiomas that, although not rare, are present in a minority of cases. Although most infantile hemangiomas with these characteristics have typical growth patterns, this case series emphasizes that a small but clinically important subset will continue to grow. Recognition of this subset can alert parents and health care providers to consider more aggressive treatment for these hemangiomas. In addition, infantile hemangiomas with prolonged growth may provide clues to the pathogenesis of hemangiomas and the mechanisms of their involution, and therefore warrant further investigation. 
